Maciej Banach: Emerging Triglyceride Targeted Therapies in MASLD and Liver Disease
Maciej Banach, Vice-Rector for the Collegium Medicum at John Paul II Catholic University of Lublin, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Frontiers in Pharmacology Journal, adding:
“Please see our recent hot topic review on ‘Triglyceride-lowering therapies for hepatic steatosis’ just accepted for the Frontiers in Pharmacology journal with Seyed Saeed Tamehri Zadeh and Peter P. Toth.
Hepatic steatosis, the hallmark of MASLD, is closely associated with elevated plasma and intrahepatic triglyceride (TG) levels, often driven by insulin resistance, atherogenic dyslipidemia, and metabolic syndrome.
Growing evidence suggests that triglyceride-lowering therapies may not only improve systemic lipid profiles but also directly impact hepatic fat accumulation and associated inflammation and fibrosis.
This review explores current and emerging TG-lowering therapies, including fibrates, omega3 fatty acids, and novel agents such as pegozafermin (an FGF21 analog), and APOC3 and angiopoietin-like protein 3 (ANGPTL3) inhibitors, in the context of hepatic steatosis and MASLD.
We discuss the mechanistic rationale behind TG-lowering as a therapeutic strategy, summarize key preclinical and clinical trial findings, and evaluate their effects on liver fat content, liver enzymes, fibrosis markers, and histologic outcomes.
While several agents demonstrate promise in reducing intrahepatic fat deposition and improving liver-related outcomes, further large-scale studies are required to establish their long-term efficacy and safety, and potential for disease modification in MASLD/MASH.
Triglyceride-targeted therapies may offer a valuable adjunct or complementary approach to current treatment paradigms focused on weight loss, insulin sensitization, and antagonizing inflammation.
The preprint version is available․”
Title: Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives
Author: Seyed Saeed Tamehri Zadeh, Peter Paul Toth, Maciej Banach
Other posts featuring Maciej Banach on Hemostasis Today.
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026
-
Jun 14, 2026, 19:38Jecko Thachil: Can We Predict and Prevent Bleeding in APL?
-
Jun 14, 2026, 19:32Highlights from Day 1 at the EHC Leadership Conference 2026
-
Jun 14, 2026, 18:01Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
-
Jun 14, 2026, 18:00Lennart Lenk: Witnessing Former Boss Deliver a Plenary Talk at EHA 2026
-
Jun 14, 2026, 18:00Priya Sriskandarajah: Great Presentations on Recent Advances in Myelofibrosis at EHA 2026